Skip to main content

Scribe Therapeutics, Inc.

SCTX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001853921

No open-market purchases or sales by Scribe Therapeutics, Inc. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q3 2026, worth $297.1M in total; ARK Invest is the only superinvestor holding it.

Key figures

Market capClose on Nov 20, 2026
$228.6M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +62 vs. previous quarter
62
13F valueReported value at the end of Q3 2026
$297.1M
Superinvestors holdingAt the end of Q3 2026
1

Price chart

From SEC filings, in USD.

Revenue, Q3 FY2026
$1.64M
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
1.67M
Shares sold short
Change
+553.3K
+49.5% vs. previous
Days to cover
4.01
At average daily volume

Superinvestors holding SCTX, Q3 2026

Go to the superinvestors tab

1 superinvestor reports holding Scribe Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

ARK Invest

Cathie Wood

0.1%

Scribe Therapeutics, Inc.'s share of the portfolio

Shares
786,921
Value
$14.5M

Latest insider trades

See all insider trades

Open-market purchases and sales by Scribe Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 29, 2026 (view filing)7:09 PM ETJul 272 daysAndreessen Marc L and 5 others10% OwnerPPurchase+333.3K$15.00+$5.00M+16.2%2.39M after
Jul 29, 2026 (view filing)6:50 PM ETJul 272 daysGordon Carl LDirectorPPurchase+1.00M$15.00+$15.0M+286.7%1.35M afterDuplicate filing
Jul 29, 2026 (view filing)6:47 PM ETJul 272 daysOrbiMed Advisors LLC and 1 otherDirectorPPurchase+1.00M$15.00+$15.0M+286.7%1.35M after
Jul 28, 2026 (view filing)9:30 PM ETJul 24-284 daysAvoro Capital Advisors LLC and 2 othersDirector, 10% Owner, Other: See RemarksPPurchaseCommon Stock, par value $0.0001 per share+2.39M$15.16+$36.3M+342.8%3.09M after3 lots
Jul 27, 2026 (view filing)9:42 PM ETJul 234 daysLucas SvetlanaChief Business OfficerPPurchase+3.00K$15.00+$45.0KNew position3.00K after
Jul 27, 2026 (view filing)9:20 PM ETJul 234 daysParrot DavidChief Financial OfficerPPurchase+2.67K$15.00+$40.0KNew position1.33K after2 lots

Top 10 13F holders, Q3 2026

See all 62 holders

The largest institutional positions in Scribe Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding SCTX in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
AH Capital Management, L.L.C.3,082,725$56.7M0.29%+3,082,725New
Avoro Capital Advisors LLC2,598,973$47.8M0.49%+2,598,973New
Ra Capital Management, L.P.1,802,178$33.2M0.33%+1,802,178New
OrbiMed Advisors LLC1,348,825$24.8M0.46%+1,348,825New
Perceptive Advisors LLC920,341$16.9M0.32%+920,341New
ARK Investment Management LLCSuperinvestorARK Invest786,921$14.5M0.08%+786,921New
Baker Bros. Advisors LP688,691$12.7M0.06%+688,691New
Price T Rowe Associates Inc684,706$12.6M0.00%+684,706New
BlackRock, Inc.679,786$12.5M0.00%+679,786New
Sanofi500,000$9.20M1.46%+500,000New

Holders of 5% or more of SCTX

See all 5 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Scribe Therapeutics, Inc..

Largest holders of SCTX from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Avoro Capital Advisors LLC13D16.37%3.09M sharesNewJul 30, 20261 filingJul 30, 2026SEC
AH Bio Fund II, L.P.13G16.30%3.08M sharesNewNov 16, 20261 filingNov 16, 2026SEC
Ra Capital Management, L.P.13G9.60%1.80M sharesNewAug 3, 20261 filingAug 3, 2026SEC
Eli Lilly & Co13D7.30%1.39M sharesNewJul 30, 20261 filingJul 30, 2026SEC
OrbiMed Advisors LLC13D7.20%1.35M sharesNewJul 29, 20261 filingJul 29, 2026SEC